Nippon India Pharma Fund · Regular · Growth
NAV
₹535.2471
as of 17 Jun 2026
Expense Ratio
1.81%
AUM
₹8,116 Cr
Lumpsum returns (CAGR)
- 1Y
- +5.52%
- 3Y
- +20.47%
- 5Y
- +12.80%
- Since Inception
- +19.80%
SIP returns (XIRR)
- 1Y
- +9.33%
- 3Y
- +12.11%
- 5Y
- +15.08%
- Since Inception
- +18.34%
Beat the benchmark — ₹500/month SIP
Same SIP in this fund vs the benchmark index
This fund
₹14,07,054
Benchmark
₹6,84,663
+₹7,22,391 extra wealth vs the benchmark index
Backtest this SIP yourselfSIP since inception — what ₹500/month became
Real NAV backtest from day one
₹1,32,000
Invested
₹14,07,054
Value today
18.3%
XIRR (p.a.)
₹500/month SIP from fund inception · Current value as of today
Try SIP Calculator with this fund's history₹1,000 lumpsum at launch — value today
Invested on the fund's first NAV date
₹1,000
Invested
₹53,588
Value today
19.8%
CAGR (p.a.)
One-time investment at fund inception · Growth purely from NAV appreciation
Try Lumpsum Calculator₹10L corpus with ₹5,000/month withdrawals since inception
Corpus is still growing despite monthly payouts
₹10,00,000
Initial corpus
₹13,20,000
Withdrawn
₹3,95,17,569
Corpus left
+₹3,98,37,569 net gain — withdrew ₹13,20,000 AND corpus grew
Plan your SWP with real NAV₹6L corpus via 12-month STP from a liquid fund at inception
₹50K/month transferred from HDFC Liquid → this fund at launch
₹6,00,000
Invested
₹2,75,56,120
Value today
-14.3%
vs lumpsum
Direct lumpsum would have beaten STP by 14.3% — but STP reduced timing risk
Model your own STP with real NAV₹1 lakh on the worst crash day — 22 Mar 2020
Worst single-day Nifty drop during this fund's life
₹1,00,000
Invested
₹4,11,038
Value today
4.1×
Multiple
Staying invested through that crash turned ₹1L into ₹4,11,038 — a 4.1× return
Read: Staying invested through crashesRisk Metrics
Trailing 1 year, annualised-0.16
Sharpe Ratio
-0.01
Alpha
0.34
Beta
-0.15
Sortino
14.19%
Std Dev
-14.84%
Max Drawdown
Performance Comparison
Thinking about Nippon India Pharma Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
- 1Sun Pharmaceutical Industries Limited13.85%
- 2Lupin Limited7.95%
- 3Dr. Reddy'S Laboratories Limited7.04%
- 4Divi'S Laboratories Limited6.61%
- 5Cipla Limited5.47%
- 6Apollo Hospitals Enterprise Limited5.01%
- 7Medplus Health Services Limited3.78%
- 8Vijaya Diagnostic Centre Limited3.36%
- 9Sai Life Sciences Limited3.27%
- 10Ajanta Pharma Limited3.19%
Investment Objective
Nippon India Pharma Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
Nippon India Pharma Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by Nippon India Mutual Fund. The fund has been operational for over 22 years. It manages assets worth ₹8,116 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE HEALTHCARE TRI. The current expense ratio is 1.81%.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •SIP investors who can benefit from rupee cost averaging during market fluctuations